Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomea Fusion, Inc.

1.85
+0.01500.82%
Volume:645.67K
Turnover:1.22M
Market Cap:109.79M
PE:-0.62
High:1.95
Open:1.85
Low:1.83
Close:1.83
52wk High:13.07
52wk Low:1.29
Shares:59.51M
Float Shares:48.85M
Volume Ratio:1.89
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9937
EPS(LYR):-3.8339
ROE:-170.54%
ROA:-68.73%
PB:3.99
PE(LYR):-0.48

Loading ...

Biomea Fusion: Promising Trials and Strategic Innovations Drive Buy Rating

TIPRANKS
·
Aug 11

Biomea Fusion price target lowered to $10 from $30 at Scotiabank

TIPRANKS
·
Aug 06

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 06

Biomea Fusion Inc : Scotiabank Cuts Target Price to $10 From $30

THOMSON REUTERS
·
Aug 06

Biomea Fusion (BMEA) Gets a Buy from Oppenheimer

TIPRANKS
·
Aug 06

Biomea Fusion Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 06

Biomea Fusion Q2 net loss narrows to $20.7 mln

Reuters
·
Aug 06

BRIEF-Biomea Fusion Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing

Reuters
·
Aug 06

Biomea Fusion Q2 EPS $(0.51) Beats $(0.54) Estimate

Benzinga
·
Aug 06

Biomea Fusion reports Q2 EPS (51c), consensus (51c)

TIPRANKS
·
Aug 06

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

GlobeNewswire
·
Aug 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 04

Biomea Fusion Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters
·
Jul 30

Biomea Fusion Inc. Files Initial Statement of Beneficial Ownership for Director Julianne Averill

Reuters
·
Jul 25

Biomea Fusion Appoints Julianne Averill to Its Board of Directors

THOMSON REUTERS
·
Jul 24

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jul 22

Biomea Fusion price target lowered to $9 from $22 at Citi

TIPRANKS
·
Jul 16

Biomea Fusion’s BMF-219 Study Update: Implications for Investors

TIPRANKS
·
Jul 04

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jun 24

Biomea Fusion Inc. Unveils Promising Data for Icovamenib, Showcasing Enhanced Glycemic Control and Weight Loss in Type 2 Diabetes Trial at ADA 2025

Reuters
·
Jun 23